J&J agreed to acquire Firefly Bio for $1 billion to add its Firelink protein-degrading platform targeting KRAS-driven tumors, expecting deal closure by end of 2026. CEO Joaquin Duato set a goal to cure certain cancers within ten years while AI tools are accelerating its drug development pipeline.
J&J Chairman and CEO Joaquin Duato outlined an ambition to cure some cancers outright within ten years and transform others into manageable long-term conditions. The company aims to secure the top position in oncology by 2030 through strategic partnerships and internal research advances.
J&J reached a $1 billion cash agreement to acquire Firefly Bio, gaining its Firelink platform designed to deliver protein-degrading drugs via antibodies to KRAS-mutated tumors. The deal is expected to close by the end of 2026, pending regulatory approvals and customary closing conditions.
J&J reported first-quarter revenue of $24.1 billion, up about 10% year-over-year, and raised its full-year 2026 sales outlook to $100.3–101.3 billion. The company also committed over $1 billion to build a cell therapy manufacturing facility in Pennsylvania to support its growing oncology and immunology pipeline.
Duato highlighted AI’s role in accelerating J&J’s drug discovery and development processes, though the precise financial benefits remain to be quantified. The integration of AI tools is expected to streamline candidate identification and optimize trial designs across therapeutic areas.
